Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Eyconis Logo
Eyconis Growth Score
57
CB Rank
41323
Heat Score
72
Eyconis is a newly formed company that will develop, manufacture and commercialize TransCon ophthalmology assets.
Founded
obfuscation
PrivateVenture - Series Unknown Redwood City, California, United States11-50 www.eyconis.com/
Overview

Eyconis
Total Funding
obfuscation
Growth Score
57
Heat Score
72

Total Funding
obfuscation
obfuscation
Venture - Series Unknown raised
obfuscation
Growth Score57
-4 pts
in past quarter
Heat Score 72
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Eyconis

CB Rank
41323
Eyconis is a newly formed company that will develop, manufacture and commercialize TransCon ophthalmology assets.
Founded
obfuscation
PrivateVenture - Series Unknown Redwood City, California, United States11-50 www.eyconis.com/

Funding Rounds

Venture - Series Unknown
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

Details

Legal Name Eyconis, Inc.
Operating Status Active
Company Type For Profit
Founders  Emmett Cunningham
About the Company
Eyconis is a newly formed company that will develop, manufacture and commercialize TransCon ophthalmology assets.
Phone Number 1650-325-5156
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

TransCon Ophthalmology Assets
A platform technology for long-acting delivery of medicines targeting eye diseases such as wet AMD, DME, RVO, and GA.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Eyconis Logo
Venture Round - Eyconis
—
obfuscation
— Venture - Series Unknown

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1

Employee Profiles

News

News and Press

News•Jan 9, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 10, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 7, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 29, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

824
79.52%
 in past month

Active Website Tech Count

25Eyconis is actively using 25 technologies for its website, according to BuiltWith. These include HSTS, Apple Mobile Web Clips Icon, and  Google Font API.
Sub-Organizations
Frequently Asked Questions

Where is Eyconis's headquarters? Eyconis is located in Redwood City, California, United States.When was the last funding round for Eyconis? Eyconis closed its last funding round on
obfuscation
from a Venture - Series Unknown round.Who are Eyconis's competitors? Alternatives and possible competitors to Eyconis may include REGENXBIO, Apellis Pharmaceuticals, and  Aldeyra Therapeutics.How much funding has Eyconis raised to date? Eyconis has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d46e5f 1)
|